These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 18790608

  • 1. Clinical studies of garenoxacin.
    Takagi H, Tanaka K, Tsuda H, Kobayashi H.
    Int J Antimicrob Agents; 2008 Dec; 32(6):468-74. PubMed ID: 18790608
    [Abstract] [Full Text] [Related]

  • 2. Oral garenoxacin in the treatment of acute bacterial maxillary sinusitis: a Phase II, multicenter, noncomparative, open-label study in adult patients undergoing sinus aspiration.
    Lopez Sisniega J, Profant M, Kostrica R, Waskin H.
    Clin Ther; 2007 Aug; 29(8):1632-44. PubMed ID: 17919545
    [Abstract] [Full Text] [Related]

  • 3. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN, Fritsche TR, Sader HS, Stilwell MG.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [Abstract] [Full Text] [Related]

  • 4. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L.
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [Abstract] [Full Text] [Related]

  • 5. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S, Phillips L, Ludwig EA, Russo R, Gajjar DA, Bello A, Ambrose PG, Costanzo C, Grasela TH, Echols R, Grasela DM.
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
    [Abstract] [Full Text] [Related]

  • 6. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
    Appelbaum PC, Gillespie SH, Burley CJ, Tillotson GS.
    Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN, Sader HS, Stilwell MG, Fritsche TR.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
    [Abstract] [Full Text] [Related]

  • 9. Bacterial resistance in the new millennium. Its impact on antibiotic selection for respiratory tract infections.
    Appelbaum PC.
    Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):5-16. PubMed ID: 19667544
    [Abstract] [Full Text] [Related]

  • 10. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
    Jacobs E, Dalhoff A, Korfmann G.
    Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
    [Abstract] [Full Text] [Related]

  • 11. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective.
    Sahm DF, Brown NP, Thornsberry C, Jones ME.
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):16-24. PubMed ID: 18931467
    [Abstract] [Full Text] [Related]

  • 12. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety.
    Bhavnani SM, Andes DR.
    Pharmacotherapy; 2005 May; 25(5):717-40. PubMed ID: 15899734
    [Abstract] [Full Text] [Related]

  • 13. [Blood and respiratory diffusion of antibiotics. A critical analysis of predictive parameters for clinical effectiveness].
    Fantin B.
    Med Mal Infect; 2006 May; 36(11-12):599-613. PubMed ID: 16837154
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of garenoxacin in elderly patients with respiratory tract infections.
    Ohsaki Y, Morita K, Takeda H, Kishino S, Okumura S, Fujiuchi S.
    Int J Antimicrob Agents; 2010 Jun; 35(6):603-5. PubMed ID: 20207522
    [Abstract] [Full Text] [Related]

  • 15. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
    Biedenbach DJ, Jones RN.
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
    [Abstract] [Full Text] [Related]

  • 16. Prulifloxacin in the treatment of acute exacerbations of COPD in cigarette smokers.
    Pasqua F, Biscione G, Crigna G, Cazzola M.
    Ther Adv Respir Dis; 2008 Aug; 2(4):209-14. PubMed ID: 19124373
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of garenoxacin in the treatment of upper respiratory tract infections.
    Ito M, Maruyama Y, Murono S, Wakisaka N, Kondo S, Hatano M, Nakanishi S, Miwa T, Yoshizaki T.
    Auris Nasus Larynx; 2012 Oct; 39(5):512-8. PubMed ID: 22078851
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of garenoxacin tablets on bacterial pneumonia: postmarketing surveillance in Japan.
    Izumikawa K, Watanabe A, Miyashita N, Ishida T, Hosono H, Kushimoto S, Kohno S.
    J Infect Chemother; 2014 Sep; 20(9):549-57. PubMed ID: 24934887
    [Abstract] [Full Text] [Related]

  • 19. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005.
    Sahm DF, Brown NP, Draghi DC, Evangelista AT, Yee YC, Thornsberry C.
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):8-15. PubMed ID: 18931466
    [Abstract] [Full Text] [Related]

  • 20. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations.
    Iannini PB.
    Curr Med Res Opin; 2007 Jun; 23(6):1403-13. PubMed ID: 17559736
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.